Cargando…

A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma

Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the correspon...

Descripción completa

Detalles Bibliográficos
Autores principales: Malaina, Iker, Martínez, Luis, Montoya, Juan Manuel, Alonso, Santos, Boyano, María Dolores, Asumendi, Aintzane, Izu, Rosa, Sanchez-Diez, Ana, Cancho-Galan, Goikoane, M. de la Fuente, Ildefonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867041/
https://www.ncbi.nlm.nih.gov/pubmed/36676104
http://dx.doi.org/10.3390/life13010155
_version_ 1784876243675512832
author Malaina, Iker
Martínez, Luis
Montoya, Juan Manuel
Alonso, Santos
Boyano, María Dolores
Asumendi, Aintzane
Izu, Rosa
Sanchez-Diez, Ana
Cancho-Galan, Goikoane
M. de la Fuente, Ildefonso
author_facet Malaina, Iker
Martínez, Luis
Montoya, Juan Manuel
Alonso, Santos
Boyano, María Dolores
Asumendi, Aintzane
Izu, Rosa
Sanchez-Diez, Ana
Cancho-Galan, Goikoane
M. de la Fuente, Ildefonso
author_sort Malaina, Iker
collection PubMed
description Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time.
format Online
Article
Text
id pubmed-9867041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98670412023-01-22 A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma Malaina, Iker Martínez, Luis Montoya, Juan Manuel Alonso, Santos Boyano, María Dolores Asumendi, Aintzane Izu, Rosa Sanchez-Diez, Ana Cancho-Galan, Goikoane M. de la Fuente, Ildefonso Life (Basel) Article Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time. MDPI 2023-01-05 /pmc/articles/PMC9867041/ /pubmed/36676104 http://dx.doi.org/10.3390/life13010155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Malaina, Iker
Martínez, Luis
Montoya, Juan Manuel
Alonso, Santos
Boyano, María Dolores
Asumendi, Aintzane
Izu, Rosa
Sanchez-Diez, Ana
Cancho-Galan, Goikoane
M. de la Fuente, Ildefonso
A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title_full A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title_fullStr A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title_full_unstemmed A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title_short A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
title_sort universal antigen-ranking method to design personalized vaccines targeting neoantigens against melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867041/
https://www.ncbi.nlm.nih.gov/pubmed/36676104
http://dx.doi.org/10.3390/life13010155
work_keys_str_mv AT malainaiker auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT martinezluis auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT montoyajuanmanuel auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT alonsosantos auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT boyanomariadolores auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT asumendiaintzane auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT izurosa auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT sanchezdiezana auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT canchogalangoikoane auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT mdelafuenteildefonso auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT malainaiker universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT martinezluis universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT montoyajuanmanuel universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT alonsosantos universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT boyanomariadolores universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT asumendiaintzane universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT izurosa universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT sanchezdiezana universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT canchogalangoikoane universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma
AT mdelafuenteildefonso universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma